A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)
- Status
- UNKNOWN
- Phase
- PHASE2
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Status
- RECRUITING
- Phase
- PHASE3
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
- Status
- COMPLETED
- Phase
- PHASE1
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
- Status
- COMPLETED
- Phase
- N/A
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
- Status
- UNKNOWN
- Phase
- PHASE2